Hala Canada English edition
Health

Health Canada recalls four lots of PegLyte bowel preparation powder over possible foreign matter

Health Canada has pulled four lots of PegLyte powder, used to prepare the bowel before medical tests, because the product may contain foreign matter that could affect its quality.

By Hala Canada News

Translated from Arabic. Read the original بالعربية

Health Canada recalls four lots of PegLyte bowel preparation powder over possible foreign matter

OTTAWA — Health Canada has issued a warning about four lots of PegLyte powder, which is used to prepare the bowel before certain medical tests and procedures, after finding that the affected products may contain foreign matter that could affect their quality.

Health authorities announced that the lots in question are being removed from the market across Canada, and urged patients and health care providers to check lot numbers before using the drug.

The recall notice was officially issued on Tuesday, Nov. 17, 2026. It covers a product distributed by Pendopharm, which belongs to Canada's Pharmascience group.

The official notice does not specify the nature of the possible foreign matter, and it does not confirm any injuries resulting from use of the drug.

What is PegLyte and what is it used for?

PegLyte is used to prepare the bowel before a colonoscopy and certain diagnostic procedures that require the digestive tract to be cleaned.

The product contains polyethylene glycol 3350, also known as macrogol, along with a mix of electrolyte salts.

Once mixed with water, the solution empties the bowel, helping doctors get a clearer view of the colon.

The drug is usually prescribed with specific instructions on the amount of fluid and the timing of doses before the medical procedure.

The quality of such preparations is particularly important because they are taken in set amounts and under medical supervision.

Four lots covered by the recall

Health Canada has identified the four lot numbers affected by the warning:

Affected lot numbers

  • 260303
  • 260304
  • 260305
  • 260306

Product name: PegLyte Powder — Drug Identification Number (DIN): 00777838

The department said the product was distributed nationally, meaning packages from the affected lots could be in different parts of the country.

Users can compare the lot number printed on their packaging with the list published in the official recall notice.

What does a Type III recall mean?

Health Canada classified the recall as Type III, a category used when the likelihood of adverse health consequences from using the product is low.

However, the classification does not mean the warning should be ignored, as checking the affected lots remains necessary to ensure safe use.

The recall carries the reference number RA-82964 and is directed at the retail level, according to details published in the department's database.

The announcement did not specify how many packages were included in the recall or what substances might be present in the powder.

What patients who have the drug should do

The department urged people who use PegLyte to first check the lot number on the package.

If the number matches one of the recalled lots, they should contact their pharmacist or doctor before deciding whether to stop or replace the treatment.

This is especially important for people with an upcoming colonoscopy, because changing the bowel preparation product may require adjusting medical instructions.

The department also advises contacting the company responsible for the recall for more information about the affected products.

Reporting symptoms and health problems

Health Canada urged users to report any side effects suspected of being linked to the product through the official reporting channels.

Reports can also be submitted about quality problems with medical products, even when no health symptoms appear.

Such reports help regulators monitor product safety and assess whether further action is needed.

The government notice remains the main source for the latest information on the lots covered by the recall, and for any later updates on the drug's safety.

More from Hala Canada